secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ovid Therapeutics Inc. (OVID)
CIK:        0001636651
Form:       8-K
Filed at:   2021-10-07T23:59:59+00:00
Accession:  0001564590-21-050376
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Ovid Therapeutics appoints Dr. Kevin Fitzgerald as director, grants stock options
--------------------------------------------------------------------------------

- Appointed Dr. Kevin Fitzgerald, Ph.D. to Board as Class II director effective Oct 6, 2021.
- Initial option for 30,000 shares at $3.44 exercise price, vesting monthly over 3 years.
- Annual cash compensation of $40,000 prorated; eligible for 15,000-share annual option grant.
- No arrangements or understandings with any other person regarding appointment; no family relationships.
- Standard indemnity agreement entered; compensation per Non-Employee Director Compensation Policy.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1636651/000156459021050376/0001564590-21-050376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1636651/000156459021050376/ovid-8k_20211006.htm
  HTML page:      https://secwatch.observer/filing/0001564590-21-050376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer